cancers-logo

Journal Browser

Journal Browser

Cancer After Kidney Transplant

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Transplant Oncology".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 1233

Special Issue Editor


E-Mail Website
Guest Editor
Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Mariana Smoluchowskiego 17, 80-214 Gdańsk, Poland
Interests: neoplasm after kidney transplantation; glomerulopathy; nephroprotection; systemic vasculitis

Special Issue Information

Dear Colleagues,

Kidney transplantation markedly enhances both the survival and the quality of life in patients with end-stage renal disease. However, the long-term use of immunosuppressive therapy—essential for preventing graft rejection—significantly increases the risk of developing de novo malignancies. In fact, post-transplant cancers have emerged as a major cause of morbidity and mortality among kidney transplant recipients, at times surpassing cardiovascular complications in certain cohorts, particularly with extended post-transplant survival.

By integrating diverse perspectives from nephrology, oncology, pathology, and transplant medicine, this Special Issue aims to advance our understanding and improve clinical care for patients confronting the dual challenge of organ transplantation and malignancy.

This Special Issue seeks to bring together cutting-edge research and clinical insights into the oncologic challenges faced by kidney transplant recipients. We welcome contributions that explore this intersection of immunology, oncology, and transplant medicine from a wide range of perspectives.

We encourage submission of the following manuscript types:
- Original research articles (clinical or translational);
- Systematic or narrative reviews.

Topics of interest include, but are not limited to, the following:
- Epidemiological trends and emerging risk factors for post-transplant malignancies.
- Oncogenic viruses in transplant recipients (e.g., EBV, HPV, and polyoma BK).
- Immune dysregulation and molecular pathways in post-transplant tumorigenesis.
- Biomarkers and strategies for early cancer detection and surveillance.
- Therapeutic dilemmas in cancer management among immunosuppressed patients.
- Immunosuppressive regimen tailoring in the context of oncologic risk.
- Comprehensive reviews and expert perspectives that synthesize current knowledge.

We look forward to your contributions.

Dr. Sławomir Lizakowski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunosuppression
  • virus-associated cancer
  • skin cancer
  • graft survival
  • kidney transplantation
  • post-transplantation lymphoproliferative disorder

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 440 KB  
Review
Malignancy of Urinary Tract in Kidney Transplant Recipients—A Narrative Review
by Sławomir Jerzy Małyszko, Letycja Rog, Ben Sprangers, Amanda DeMauro Renaghan, Mitchell H. Rosner, Rafal Stec, Leszek Kraj, Jacek Stanisław Malyszko and Jolanta Małyszko
Cancers 2026, 18(4), 695; https://doi.org/10.3390/cancers18040695 - 20 Feb 2026
Viewed by 983
Abstract
Kidney transplantation is the optimal treatment for end-stage kidney failure. However, after successful kidney transplantation, patients require long-term immunosuppression. Due to immunosuppressive therapy, the development of malignancies is more common in solid organ transplant recipients than in the general population. Because renal transplantation [...] Read more.
Kidney transplantation is the optimal treatment for end-stage kidney failure. However, after successful kidney transplantation, patients require long-term immunosuppression. Due to immunosuppressive therapy, the development of malignancies is more common in solid organ transplant recipients than in the general population. Because renal transplantation has been performed for many decades—much longer than other solid organ transplants—data on malignancies in kidney allograft recipients are the most comprehensive. Malignancies are the third most common cause of death in kidney allograft recipients, after cardiovascular disease and infections. In kidney allograft recipients, malignancies may develop de novo, be transmitted with the transplanted organ, or arise from previously present but undiagnosed cancers in the recipient. Over 90% of malignancies in renal allograft recipients are de novo. In this review, we first present the epidemiology of malignancies after kidney transplantation. Subsequently, the most common urinary tract malignancies, along with their diagnosis, treatment, and screening, are discussed. We also outline the limitations of the published data, propose research priorities, and identify existing gaps and unmet needs. Full article
(This article belongs to the Special Issue Cancer After Kidney Transplant)
Show Figures

Figure 1

Back to TopTop